Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 445.00 114,377 08:00:00
Bid Price Offer Price High Price Low Price Open Price
440.00 450.00 445.00 445.00 445.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 26.17 4.75 9.14 48.7 202
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:29 O 7,200 442.50 GBX

Tristel (TSTL) Latest News (1)

More Tristel News
Tristel Takeover Rumours

Tristel (TSTL) Discussions and Chat

Tristel Forums and Chat

Date Time Title Posts
04/8/202022:08The TRISTEL story2,898
14/9/201814:56MRSA cleaner249
15/7/201513:01Tristel PLC: Cleaning up the sector340
03/1/201004:54tristel with charts-
13/2/200607:10TSTL with Charts & News3

Add a New Thread

Tristel (TSTL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-07 16:40:38442.507,20031,860.00O
2020-08-07 16:15:00442.5027,352121,032.60O
2020-08-07 16:15:00442.3325,000110,582.50O
2020-08-07 16:06:30440.891,8508,156.46O
2020-08-07 15:27:46442.502,1119,341.18O
View all Tristel trades in real-time

Tristel (TSTL) Top Chat Posts

Tristel Daily Update: Tristel Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 445p.
Tristel Plc has a 4 week average price of 397.50p and a 12 week average price of 397.50p.
The 1 year high share price is 534p while the 1 year low share price is currently 264p.
There are currently 45,296,533 shares in issue and the average daily traded volume is 41,887 shares. The market capitalisation of Tristel Plc is £201,569,571.85.
james188: On the subject of share based payments, the concern is understandable and I thought that Phil Oakley made some valid points in the IC webcast today. That said, I personally don't have problem with senior management being rewarded well for growing the company significantly year on year and generating excellent shareholder total returns. I first remember this issue coming to the fore for TSTL in early 2016, when the share price was around 110p.The complaint was that the 2015 LTIP was incorrectly calibrated and led to windfall gains. It had been 96p when the scheme was documented. A revised scheme (the 2018 LTIP) was announced in November 2017 and set out in some detail at that time - options granted to senior management vested if the share price achieved 350p, 425p and 500p for a minimum three month period.There was a considerable amount of adverse comment at the time, but for all that, I was the only external shareholder who turned up for the 2017 AGM and asked the company about the arrangements. Responses were provided by David Orr (head of the Remuneration Committee) and Geoff Nash (company broker). I have not located my detailed notes, but I recall that I was told that a detailed comparison had been carried out with other bio companies - many of which were still loss making, unlike TSTL. The conclusion was that the proposed TSTL arrangements were fully in line and not towards the top end. You can make the argument (as certain well known and respected commentators certainly have) that the product sells itself, irrespective of the quality of management. I do not share that view. I think that the company is at a potential inflection point and that senior management needs to be laser focused.The SBP are certainly an issue, but not the central one for me.
james188: The director sales were largely to fund exercise/tax costs.I don't have an issue with that and I am much more interested in the long term trend of the share price and the company's prospects. I continue to believe that the company is still at a fairly early stage in its evolution. There are a lot of further opportunities that should be relatively easy to convert, both geographically and in product range.The fact that management is cautious is a plus point for me, but I hope (and expect)that they seize the present opportunities. I have lots of questions (which I have set out today in an e-mail to the company),but I saw today as an obvious buy opportunity. The share price has always been volatile and I don't suppose that that will change within the foreseeable future.
james188: I have been topping up materially of late. TSTL has never been really cheap and I first invested relatively late in September 2005, having tracked it for just over 12 months. I should have got in much earlier. I take the view that TSTL is still at an early stage in its journey. The UK NHS market is obviously very important, but TSTL now sells most of its product outside the UK. It has lots of new markets where it has hardly started - even if you forget the US opportunity (which I don't).China, India and South America and others all spring to mind. I also expect (and hope) that it will get involved in the consumer market, most probably with a major partner in order to deliver at scale. The COVID virus has boosted the share price, but much less than some other COVID related stocks. To me, it is blindingly obvious that products that zap the ever increasing bugs that we are having to confront will be in demand. Other virus strains will doubtless appear over the next few months and years. This is an obvious roll out.
james188: I expect that they have done very well. However, it is three months since we had any update and so the share price has drifted, because competitors have given more recent information. A bit tedious that we have to wait until 22nd July for an update.
makw61: The fall in share price coincided with the announcement that the NHS were stopping routine operations so i guess it reflects concern over reduced demand for instrument decontamination etc. Seems a bit overdone - with high PE stocks most of the value is well into the future, not current year earnings, and the long term prospects have likely increased post Covid 19.
metis20: Piedro - "At Tristel the exertion seems minimal, repeating the old formula and letting the momentum carry them forward." What evidence do you have for this?! Did you attend a recent Investor Presentation? The impression I obtained at the late afternoon session was of a decidedly hard working and innovative duo leading the company. Https:// Share holder approval was of course required. Vesting conditions - that was when the share price was £2.75 · One-third will vest upon the achievement of a share price of £3.50; · One-third will vest upon the achievement of a share price of £4.25; · One-third will vest upon the achievement of a share price of £5.00. Between 4 August 2015 and 1 November 2017, the Company's share price has increased from 96 pence to 275 pence, and the Company's market capitalisation has increased from £40 million to £118 million. The Board considers that the 2015 Scheme has successfully met its objectives.
salchow: "Profits up, share price down..why?" US approval takes longer and costs more than anticipated. Already an expensive share.
metis20: From FY (ending June 2018) final results - "The corollary to achieving these targets is that we are likely to be highly cash generative given the operational cash requirements of the business. If the Board considers that there are no earnings enhancing opportunities to invest excess cash, a special dividend will be paid to shareholders. The Board's pursuit of these financial objectives is grounded in the belief that consistent and sustainable increases in earnings and dividends will, over time, result in share price growth." Https:// From H1 (ending Dec 2017)report - "During the first half a final dividend of 2.63 pence per share was paid, totalling £1.1m. At the period end cash was £4.9m compared to £3.9m on 31 December 2016. We will pay an interim dividend of 1.6 pence per share on 12 April 2018 to shareholders on the register on 23 March 2018, with an ex-dividend date of 22 March 2018. Our policy is to cover the dividend with earnings by at least two times and pay 40% as an interim and 60% as a final." Https://
piedro: To quote the Walbrock report ... "Look to the cash flow statement, and you see share-based payment rose to £665k from £121k. Management rewarded themselves with large bonuses, despite missing earnings forecast. The cancellation of its special dividends took the yield down to 1.6% from approx. 2.5%. To be fair to management, the company share price rose from 30 pence to £2.59, an increase of 760% in the last five years. Surely, management deserves their bonuses for delivering long-term gains to shareholders." - long term investors will remember the pain back in 2010 when the management took the share price from 60p down to 20p - they had to get in outside help to pick the company up again - now again ... "We are working to appoint new Non-Executive Directors to bring fresh ideas and new experiences to our Board" {Annual Report} - the present chairman was only supposed to be 'Interim' - going by past experience, I am thinking that circumstances are obliging him to let go and there may yet be unwelcome revelations to come - I would not be surprised if it was not this same management that is stifling the young talent within the company AIMO, BWDIK GLA and ride the storm.
melton john: "they do not provide the incentive to improve the share price" One-third will vest upon the achievement of a share price of GBP3.50; One-third will vest upon the achievement of a share price of GBP4.25; One-third will vest upon the achievement of a share price of GBP5.00. Why on earth would you be happy if they vested "at or near the current share price" Have I missed something?
Tristel share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200808 07:04:21